Heterocyclic derivative and pharmaceutical composition comprising the same
US-9212130-B2 · Dec 15, 2015 · US
Nicotinamides as JAK kinase modulators
US9102625B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9102625-B2 |
| Application number | US-201113286984-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 1, 2011 |
| Priority date | Nov 1, 2010 |
| Publication date | Aug 11, 2015 |
| Grant date | Aug 11, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound having the formula: or a tautomer thereof or a pharmaceutically acceptable salt or hydrate thereof wherein: each X 1 or X 2 is independently H or halogen; D 1 is selected from the group consisting of: -L 1 -phenyl, wherein the phenyl is further optionally substituted with from 1 to 3 substituents, R 1…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9102625B2 cover?
- The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK kinase activity, methods of …
- Who is the assignee on this patent?
- Bauer Shawn M, Song Yonghong, Xu Qing, and 7 more
- What technology area does this patent fall under?
- Primary CPC classification C07D213/82. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).